UroGen Pharma Ltd. acquires next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc.
02/20/25, 1:36 PM
Location
princetonsan diegoIndustry
biotechnology
healthcare
biotechnology
UroGen Pharma Ltd. expands its oncology pipeline portfolio through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. In addition, UroGen also announced strategic research collaborations to explore the potential of its proprietary RTGel technology to enhance clinical effectiveness of multiple immunotherapies.
Company Info
Location
400 alexander park drive
Princeton, New Jersey, United States
Company info
UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results.